Original citation: J Clin Invest. 2017;127(7):2705–2718. https://doi.org/10.1172/JCI92335

Citation for this corrigendum: J Clin Invest. 2017;127(9):3557. https://doi.org/10.1172/JCI96860

The last two sentences in the first paragraph of the Discussion section were incorrect. The correct sentences are below.

Recently described “ImmTAC” molecules use a TCR-based recognition domain offering similar reactivity to TCRm Abs and demonstrate high affinity (42). Also, TCRm Abs such as Pr20 can target these “undruggable” proteins with high affinity for redirected immune-mediated cytolysis.

The authors regret the error.

Footnotes

See the related article at A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens.

中文翻译：

---

治疗性 T 细胞受体模拟抗体靶向肿瘤相关 PRAME 肽/HLA-I 抗原

原始引文：J Clin Invest。2017；127(7):2705–2718。https://doi.org/10.1172/JCI92335

本勘误表的引用：J Clin Invest。2017；127(9):3557。https://doi.org/10.1172/JCI96860

讨论部分第一段的最后两句话不正确。正确的句子如下。

最近描述的“ImmTAC”分子使用基于 TCR 的识别域，提供与 TCRm Ab 相似的反应性，并表现出高亲和力 (42)。此外，Pr20 等 TCRm Ab 可以以高亲和力靶向这些“不可成药”的蛋白质，从而实现重定向免疫介导的细胞溶解。

作者对这个错误表示遗憾。

脚注

请参阅相关文章：治疗性 T 细胞受体模拟抗体靶向肿瘤相关 PRAME 肽/HLA-I 抗原。